AlphAIAlphAI — Financial news for AI agents
zacks.comOCT 302 min read$REGN

REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up

Regeneron Pharmaceuticals reported Q3 2026 adjusted EPS of $20.07, beating estimates. Revenue rose 36% YoY to $5.12B, driven by Dupixent, Eylea HD, and Libtayo. Eylea HD sales grew 62% YoY, while legacy Eylea declined 41%. Collaboration revenues surged 52% YoY to $3.00B. The company raised R&D expense guidance but lowered SG&A expense guidance. According to Zacks Investment Research, shares rose on the results.

Original reporting
zacks.com
Published Oct 30, 2026, 6:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 7:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up — source image
Source · zacks.com
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

Earnings beat and guidance lift suggest near‑term upside, but higher expense guidance tempers long‑term outlook.

02

Market read

Strong earnings and guidance revisions make REGN a focal point for biotech traders today.

03

What to watch

Guidance raises R&D expense range, which may weigh on cash flow despite revenue growth.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Regeneron reported Q3 2026 results, beating consensus on both earnings and revenue, and updated guidance.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Q3 2026 earnings beat estimates with EPS $20.07 vs $16.08 and revenue $5.12B vs $4.55B, driving a stock rise.

Expected impact

upward pressure as market prices in the earnings beat and raised guidance

Evidence & confidence

Large‑cap earnings beat with strong guidance revisions typically moves the stock in the same session.

Market effects

Sector

Biotech sector may see broader rally on strong immunology collaboration results.

Regional

U.S. markets likely to open higher on biotech earnings momentum.

Global

International partners (Sanofi, Bayer) may see modest impact from collaboration revenue trends.

Counterpoint

What could challenge this read

Higher R&D spend and declining legacy Eylea sales could pressure margins if growth slows.

Key entities

  • company
    Regeneron Pharmaceuticals

    Biotech firm reporting Q3 earnings beat.

  • partner
    Sanofi

    Collaboration partner with increased revenue contribution.

Read at source← All news

StoryRegeneron posts Q3 2026 earnings beat, revenue up 36% and receives $1 billion Sanofi upfront

Also covered by

5 outlets

Related articles

OCT 30
$REGNMed

Raymond James raises Regeneron stock price target to $1,020 on strong quarter

Raymond James raised its price target for Regeneron (NASDAQ:REGN) to $1,020, citing strong Q3 2026 performance and positive drug developments. The stock trades at $928 with a $92.4B market cap. Dupixent and Eylea HD are key growth drivers. Regeneron reported Q3 2026 earnings of $20.07 per share and revenue of $5.12B, exceeding estimates. 10 analysts revised earnings upwards. The company holds $16.2B in cash and projects $26B by year-end 2027.

investing.com2 min
OCT 30
$REGNHighAI 9/10

Regeneron (REGN) stock trades up, here is why

Regeneron (REGN) shares rose 11.5% after reporting Q3 2026 revenue of $5.1B, up 36%, and EPS of $20.07, up 70%. The company cited record sales for key drugs and expanded its alliance with Sanofi. REGN also announced pipeline milestones and updated trial data for Libtayo. The stock has gained 17.3% YTD, reaching a 52-week high of $910.25.

theglobeandmail.com2 min
OCT 30
$REGNHighAI 9/10

Regeneron Q3 Revenue Rises 36%; Pipeline Advances, FDA Catalysts Ahead; Stock Up

Regeneron reported Q3 2026 revenue of $5.116B, up 36% YoY, with GAAP net income rising 33% to $1.949B. Key products like Dupixent and EYLEA HD saw significant sales growth. The company expanded its Sanofi collaboration, receiving a $1B upfront payment. Regeneron also advanced its pipeline with FDA approvals and positive clinical trial results. The stock is up 11.46%.

rttnews.com3 min
OCT 30
$REGNMedAI 8/10

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call

Regeneron (REGN) reported Q3 earnings, highlighting pipeline milestones. The company expects an FDA decision for cemdisiran in November and plans to present initial data for its CIDEB-targeting siRNA. It also reported positive results for ubamatamab in ovarian cancer. Sanofi collaboration revenue reached $2.7B, with a $1B upfront payment expected in Q4. Regeneron generated $2.9B in free cash flow and plans $3B in share repurchases for the year.

finance.yahoo.com3 min